Intellectual disability-hypotonic facies syndrome, X-linked 1

1. Disease Information

1.1 Concise overview (current understanding)

ATR-X syndrome is a rare, primarily male-affecting X-linked neurodevelopmental disorder caused by hypomorphic germline variants in ATRX, characterized by intellectual disability (ID) often accompanied by alpha-thalassemia and multi-system congenital anomalies (facial dysmorphism, hypotonia, skeletal and urogenital abnormalities, and hematologic findings). (tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2, pang2023thechromatinremodeler pages 1-2)

1.2 Key identifiers and nomenclature

A structured summary of the identifiers and naming used in the retrieved literature is provided below.

Table: This table summarizes the nomenclature and core identifiers for ATR-X syndrome from the retrieved evidence, including synonyms, OMIM entries, inheritance, prevalence estimates, and publication sources. It also flags identifier systems that were not explicitly available in the retrieved full text.

• OMIM: ATR-X syndrome is explicitly linked to OMIM 301040 in multiple retrieved sources. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)
• Related ATRX disorder label in retrieved text: MRXHF1 (X-linked intellectual disability-hypotonic facies syndrome-1) is referenced as an ATRX-related disorder with OMIM 309580. (wang2024identificationofa pages 1-2)
• Orphanet/ICD/MeSH/MONDO: Not explicitly present in the retrieved full text snippets and therefore not reportable here as evidence-backed codes. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)

1.3 Synonyms / alternative names

Commonly used synonyms in the retrieved literature include: “ATR-X syndrome”, “ATRX syndrome”, “alpha-thalassemia/intellectual disability, X-linked”, and “alpha-thalassemia X-linked intellectual disability”. (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)

1.4 Evidence source type

The information synthesized here is derived from (i) aggregated disease-level reviews and cohorts, and (ii) individual case reports with literature review, as well as model organism work (mouse). (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, lupu2024pyridostigmineasa pages 2-3)

2. Etiology

2.1 Disease causal factors

Primary cause: germline pathogenic variants in ATRX (Xq21.1), encoding a SNF2-family chromatin remodeling protein with key functional domains (ADD and helicase/ATPase-like domains). (wang2024identificationofa pages 1-2, pang2023thechromatinremodeler pages 1-2)

Variant spectrum and general rule: In ATR-X syndrome, alleles are typically hypomorphic (commonly missense; also small in-frame/other changes), and complete null alleles are not typically seen clinically, consistent with embryonic lethality when ATRX is fully deleted in mouse. (tillotson2023anewmouse pages 1-4, maganaacosta2025atrxfrom pages 13-13)

2.2 Risk factors

For an X-linked Mendelian disorder, the principal “risk factors” are genetic: - Sex (male/hemizygous): male predominance is expected because hemizygous males are typically affected, while female carriers are often less affected, consistent with X-inactivation effects. (yuan2024mutantatrxpathogenesis pages 1-2, maganaacosta2025atrxfrom pages 13-13) - Family history / carrier mother: implied by X-linked inheritance (not quantified in retrieved snippets). (maganaacosta2025atrxfrom pages 13-13)

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved full text.

2.4 Gene–environment interactions

No clear gene–environment interaction evidence specific to ATR-X syndrome was found in the retrieved full text.

3. Phenotypes

3.1 Phenotype spectrum and key clinical manifestations

Core features repeatedly described include: - Intellectual disability / developmental delay (universal in many cohorts) - Alpha-thalassemia / HbH features (common but not universal) - Craniofacial dysmorphism - Hypotonia - Urogenital anomalies - Skeletal abnormalities - Gastrointestinal complications (can be severe)

These are summarized across recent reviews and patient-based syntheses. (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4, yuan2024mutantatrxpathogenesis pages 1-2)

3.2 Phenotype frequencies (recent quantitative data)

Recent cohort-level percentages extracted from a 2024 case + systematic literature synthesis are summarized below.

Table: This table summarizes key clinical features of ATR-X syndrome with cohort frequencies reported in Wang et al. 2024. It is useful for rapid phenotype curation and notes where the full mutation-type and domain-specific distributions can be found.

Additionally, Table 1 and Table 2 with expanded phenotype frequencies stratified by mutation type and protein domain were identified in the Wang et al. 2024 paper images. (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce)

3.3 Gastrointestinal phenotypes and quality-of-life impact

Gastrointestinal involvement can be clinically dominant and life-threatening in some individuals. A 2024 ATR-X case report and literature review emphasized that ATR-X patients may have gastroesophageal and motility manifestations “most commonly gastroesophageal issues, including chronic gastroesophageal reflux (GER), drooling and constipation.” (lupu2024pyridostigmineasa pages 2-3)

Severe GI complications discussed in this review include intestinal malrotation/volvulus and recurrent bowel volvulus; the review notes such issues can contribute to major morbidity and even mortality. (lupu2024pyridostigmineasa pages 2-3)

3.4 Suggested HPO terms (examples)

Examples are included in the phenotype-frequency artifact and include: - Intellectual disability (HP:0001249) - Seizures (HP:0001250) - Congenital heart defect (HP:0001644) - Autistic behavior (HP:0000729) - HbH inclusion bodies (HP:0005523)

(See | Phenotype | HPO term suggestion | Frequency / notes | Evidence / source | |---|---|---|---| | Intellectual disability | HP:0001249 Intellectual disability | 100% (reported as 43/43 in the reviewed cohort); described as universal in the summarized ATRX cohort. | Wang et al. 2024 review/case synthesis; cohort percentages extracted from text discussing genotype–phenotype relationships (wang2024identificationofa pages 7-8) | | Alpha-thalassemia / HbH inclusion | HP:0001927 Abnormal hemoglobin; HP:0005523 Hemoglobin H inclusion bodies; HP:0001878 Hemolytic anemia | 41.86% overall (18/43) in the summarized cohort; alpha-thalassemia is common but not universal, so absence does not exclude ATR-X syndrome. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Autism / behavioral problems | HP:0000729 Autistic behavior; HP:0000708 Behavioral abnormality | 44.19% overall (19/43); reported as a recurrent neurobehavioral feature. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Epilepsy | HP:0001250 Seizure | 23.26% overall (10/43); reported among recurrent neurologic manifestations and noted as more prevalent in frameshift variants than missense variants in the broader review. | Wang et al. 2024 phenotype summary and genotype–phenotype discussion (wang2024identificationofa pages 7-8, wang2024identificationofa pages 1-2) | | Congenital heart defects | HP:0001627 Abnormal heart morphology; HP:0001644 Congenital heart defect | 18.60% overall (8/43); reported as an associated but less frequent congenital manifestation. | Wang et al. 2024 phenotype summary (wang2024identificationofa pages 7-8) | | Mutation-type/domain stratification note | Not applicable | Full phenotype distributions stratified by mutation type are in Table 1, and genotype–phenotype relationships by affected protein domain are in Table 2 of Wang et al. 2024; these tables were identified from the page images. | Table-image extraction identifying Table 1 and Table 2 as the key frequency/genotype–phenotype tables (wang2024identificationofa media 3e3625e3, wang2024identificationofa media bc05e6ce) |

Table: This table summarizes key clinical features of ATR-X syndrome with cohort frequencies reported in Wang et al. 2024. It is useful for rapid phenotype curation and notes where the full mutation-type and domain-specific distributions can be found..)

4. Genetic / Molecular Information

4.1 Causal gene

• ATRX (Xq21.1) is the causal gene for ATR-X syndrome (OMIM 301040). (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)

4.2 Pathogenic variant classes and genotype–phenotype notes

A 2024 case report with literature synthesis notes that missense variants are most common overall and that the ADD and helicase-like domains are frequently affected; it also reports mutation-type associations (e.g., frameshift variants showing higher prevalence of epilepsy, congenital heart disease, urogenital, acoustic, and optical defects compared with missense). (wang2024identificationofa pages 1-2)

4.3 Functional consequences and molecular functions (current understanding)

ATRX is described as a chromatin-remodeling ATPase involved in transcriptional regulation, DNA damage repair, and heterochromatin maintenance. (tillotson2023anewmouse pages 1-4)

Mechanistic reviews emphasize ATRX roles in chromatin remodeling and genomic integrity, including cooperating with DAXX to deposit histone variant H3.3 at repetitive regions (e.g., telomeric/pericentromeric heterochromatin). (pang2023thechromatinremodeler pages 1-2, vaisfeld2022phenotypicspectrumand pages 1-2)

4.4 Epigenetic information and episignatures

DNA methylation episignatures are increasingly used as functional biomarkers in neurodevelopmental Mendelian disorders; ATRX has a published episignature that has been independently evaluated and shown high diagnostic performance (see Diagnostics section). (husson2024episignaturesinpractice pages 1-2, trajkova2024dnamethylationanalysis pages 1-2)

5. Environmental Information

No specific environmental toxins, lifestyle factors, or infectious triggers were identified in the retrieved full text as contributing causes for ATR-X syndrome (a genetic disorder).

6. Mechanism / Pathophysiology

6.1 Mechanistic chain (high-level)

ATRX hypomorphic loss → altered recruitment/function of a chromatin remodeling ATPase at heterochromatin and other genomic regions → impaired regulation of transcription, heterochromatin maintenance, and genome stability/replication stress responses → neurodevelopmental defects (ID, microcephaly-like phenotypes), multi-system congenital anomalies, and hematologic dysregulation consistent with alpha-thalassemia in many patients. (tillotson2023anewmouse pages 1-4, tillotson2023anewmouse pages 16-22, pang2023thechromatinremodeler pages 1-2)

6.2 Cell and molecular processes implicated (evidence-backed themes)

• Chromatin remodeling and transcriptional regulation: ATRX is repeatedly described as a chromatin remodeler/transcriptional regulator. (pang2023thechromatinremodeler pages 1-2, tillotson2023anewmouse pages 1-4)
• DNA damage/replication stress responses: ATRX is described as involved in DNA damage repair; the patient-mutation knock-in mouse paper also frames ATRX in this functional context. (tillotson2023anewmouse pages 1-4)
• Heterochromatin maintenance / recruitment via histone marks: the knock-in mouse model highlights disrupted heterochromatin recruitment mediated by ADD-domain binding to H3K9me3, stating “This recruitment is severely disrupted by the R245C mutation.” (tillotson2023anewmouse pages 16-22)

6.3 Suggested ontology terms

• GO (biological process; examples): chromatin remodeling; DNA repair; regulation of transcription; response to replication stress. (tillotson2023anewmouse pages 1-4, tillotson2023anewmouse pages 16-22)
• GO (cellular component; examples): heterochromatin; nucleus. (tillotson2023anewmouse pages 16-22)
• Cell Ontology (CL; examples): neurodevelopmental relevance suggests neural progenitors/neurons; the mouse model includes hippocampal neuron phenotypes (neurite/dendrite changes). (tillotson2023anewmouse pages 13-16, tillotson2023anewmouse pages 10-13)

7. Anatomical Structures Affected

Evidence supports multi-system involvement: - Central nervous system: neurodevelopmental phenotype; mouse knock-in shows reduced brain weight and cerebellar/corpus callosum structural changes. (tillotson2023anewmouse pages 10-13) - Hematopoietic system: alpha-thalassemia is a defining feature for many patients (not universal). (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 7-8) - Gastrointestinal tract: severe dysmotility/GER/constipation and complications (malrotation/volvulus) reported. (lupu2024pyridostigmineasa pages 2-3) - Urogenital system: genital abnormalities and urogenital defects are part of the typical clinical description. (wang2024identificationofa pages 1-2, tillotson2023anewmouse pages 1-4)

8. Temporal Development

Onset is typically congenital/early childhood consistent with a neurodevelopmental disorder; the knock-in mouse model is framed as developmental rather than degenerative (normal head circumference at birth but later differences in brain size/structure). (tillotson2023anewmouse pages 10-13)

9. Inheritance and Population

9.1 Inheritance

ATR-X syndrome is X-linked and affects “primarily… hemizygous males,” with females often being carriers due to X-inactivation effects. (tillotson2023anewmouse pages 1-4, maganaacosta2025atrxfrom pages 13-13)

9.2 Epidemiology

A 2024 review/case synthesis reports the condition as rare with an estimated prevalence of approximately 1/30,000–1/40,000 male newborns. (wang2024identificationofa pages 1-2)

10. Diagnostics

10.1 Genetic testing (current practice)

WES/NGS is used to identify ATRX variants in suspected cases; one 2024 report diagnosed an ATRX-related phenotype by whole-exome sequencing and applied ACMG criteria for classification. (wang2024identificationofa pages 1-2)

10.2 DNA methylation episignatures (recent developments; 2023–2024 prioritized)

Recent work supports using genome-wide DNA methylation “episignatures” as diagnostic/variant-interpretation tools in neurodevelopmental disorders: - A 2024 independent evaluation of published episignatures reported 100% specificity of the procedure and that the ATRX episignature displayed 100% sensitivity in that dataset. (husson2024episignaturesinpractice pages 1-2) - A 2024 clinical study applying episignatures in neurodevelopmental disorders reported the expected episignature in 53/59 (90%) validation cases and identified an ATRX-associated case via methylation profiling in the test cohort. (trajkova2024dnamethylationanalysis pages 1-2)

10.3 Long-read sequencing integrated genomics + methylation (emerging implementation)

Nanopore long-read sequencing approaches can simultaneously call genetic variants and derive methylation signatures: - A 2024 preprint reported classifier-recognized episignature assignment in 17/20 patients and classification of all healthy controls as controls; the paper also illustrates how episignature and segregation data can support benign interpretation of an ATRX VUS in a complex case. (geysens2024nanoporesequencingbasedepisignature pages 11-14) - A 2025 long-read methylome study included ATR-X syndrome cases and extracted ATR-X-specific long-read DNA methylation signatures as alternatives to array-based signatures. (mizuguchi2025diagnosticutilityof pages 1-2)

A structured diagnostic summary is provided below.

Table: This table summarizes current diagnostic modalities for ATRX syndrome, spanning standard genomic sequencing and newer DNA methylation episignature approaches. It highlights recent validation and implementation data that are useful for clinical interpretation, especially when variants are uncertain.

11. Outcome / Prognosis

The retrieved evidence is insufficient to provide rigorous survival estimates or life expectancy distributions. However, severe gastrointestinal complications (e.g., malrotation/volvulus) are described as potential causes of severe outcomes including death in some reported contexts, highlighting the need for proactive surveillance and management. (lupu2024pyridostigmineasa pages 2-3)

12. Treatment

12.1 Supportive and symptom-directed management (real-world implementation)

No disease-modifying therapy is established in the retrieved evidence; management is supportive and phenotype-driven.

Gastrointestinal dysmotility: A 2024 case report and review describes pyridostigmine as a potential option and includes a strongly positive single-patient outcome: the patient “was started on oral pyridostigmine… gradually increased… [and] after a year of sustained treatment, his gastrointestinal symptoms fully resolved.” (lupu2024pyridostigmineasa pages 2-3)

The same review summarized safety across pediatric cases: “of the nine patients documented… only one experienced minor side effects (abdominal pain and cramps).” (lupu2024pyridostigmineasa pages 2-3)

12.2 Experimental / emerging therapeutics

A 2025 source summarized exploratory evidence that 5-aminolevulinic acid (5-ALA) may improve cognitive outcomes in a subset of ATR-X patients in a small phase 2 trial (5 participants; 2 responders) and was described as safe/tolerated in that report. (bertocchi2025matrixmetalloproteinase9and pages 57-61)

12.3 MAXO suggestions

A structured treatment-management table with MAXO-style action concepts is provided below.

Table: This table summarizes reported management evidence for ATR-X syndrome, emphasizing gastrointestinal dysmotility interventions and the exploratory 5-ALA cognitive trial. It is useful for distinguishing supportive care from early experimental therapy and for mapping interventions to MAXO-style treatment concepts.

13. Prevention

Primary prevention is not applicable for a monogenic X-linked condition in the usual public health sense; prevention focuses on: - Genetic counseling for at-risk families (carrier testing, reproductive counseling) - Prenatal/preimplantation genetic testing where appropriate and locally available

The retrieved texts emphasize that X-linked inheritance and skewed X-inactivation in females complicate presentation and interpretation, reinforcing the need for genetics-guided counseling. (maganaacosta2025atrxfrom pages 13-13, geysens2024nanoporesequencingbasedepisignature pages 11-14)

14. Other Species / Natural Disease

No naturally occurring veterinary ATRX syndrome analogs were identified in the retrieved full text.

15. Model Organisms

15.1 Mouse model (patient-mutation knock-in; key recent development)

A patient-relevant knock-in mouse model was generated carrying the common patient mutation (R246C; modeled as AtrxR245C/y in mice). The authors state it is “the first patient mutation knock-in model of ATR-X syndrome, carrying the most common patient mutation, R246C,” and report that the mice “recapitulate several aspects of the patient disorder, including craniofacial defects, microcephaly and impaired neurological function.” (tillotson2023anewmouse pages 1-4)

A key mechanistic observation is that ADD-domain–mediated recruitment to heterochromatin is disrupted; the paper states: “This recruitment is severely disrupted by the R245C mutation.” (tillotson2023anewmouse pages 16-22)

15.2 Model limitations

The same mouse model did not recapitulate all hallmark human features, including alpha-thalassemia and genital abnormalities, which is important for translational interpretation. (tillotson2023anewmouse pages 13-16)

Notes on evidence gaps vs. template requirements

• MONDO/Orphanet/ICD/MeSH codes: not available in the retrieved full text; should be imported from the authoritative databases directly (OMIM/Orphanet/MONDO/MeSH/ICD). (tillotson2023anewmouse pages 1-4, wang2024identificationofa pages 1-2)
• Large natural history cohorts and survival statistics: not identified in the retrieved full text; additional registry/natural history sources would be required.

References

1. (tillotson2023anewmouse pages 1-4): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

2. (yuan2024mutantatrxpathogenesis pages 1-2): Kejia Yuan, Yan Tang, Zexian Ding, Lei Peng, Jinghua Zeng, Huaying Wu, and Qi Yi. Mutant atrx: pathogenesis of atrx syndrome and cancer. Frontiers in Molecular Biosciences, Oct 2024. URL: https://doi.org/10.3389/fmolb.2024.1434398, doi:10.3389/fmolb.2024.1434398. This article has 7 citations.

3. (pang2023thechromatinremodeler pages 1-2): Ying Pang, Xu Chen, Tongjie Ji, Meng Cheng, Rui Wang, Chunyu Zhang, Min Liu, Jing Zhang, and Chunlong Zhong. The chromatin remodeler atrx: role and mechanism in biology and cancer. Cancers, 15:2228, Apr 2023. URL: https://doi.org/10.3390/cancers15082228, doi:10.3390/cancers15082228. This article has 51 citations.

4. (wang2024identificationofa pages 1-2): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

5. (maganaacosta2025atrxfrom pages 13-13): Mauro Magaña-Acosta and Viviana Valadéz-Graham. atrx : from chromatin remodeling to disease. genesis, Nov 2025. URL: https://doi.org/10.1002/dvg.70031, doi:10.1002/dvg.70031. This article has 1 citations and is from a peer-reviewed journal.

6. (lupu2024pyridostigmineasa pages 2-3): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

7. (wang2024identificationofa pages 7-8): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

8. (wang2024identificationofa media 3e3625e3): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

9. (wang2024identificationofa media bc05e6ce): Yishan Wang, Qizhou Ma, Jing Chen, Shaoxin Li, Feifei Zheng, Lei Shi, Xiaoshun Li, Sinan Li, Guanglei Tong, and Hong Li. Identification of a novel frameshift variant of the atrx gene: a case report and review of the genotype–phenotype relationship. BMC Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s12887-024-05088-0, doi:10.1186/s12887-024-05088-0. This article has 4 citations and is from a peer-reviewed journal.

10. (vaisfeld2022phenotypicspectrumand pages 1-2): Alessandro Vaisfeld, Sara Taormina, Alessandro Simonati, and Giovanni Neri. Phenotypic spectrum and molecular findings in 17 atr-x syndrome italian patients: some new insights. Genes, 13:1792, Oct 2022. URL: https://doi.org/10.3390/genes13101792, doi:10.3390/genes13101792. This article has 6 citations.

11. (husson2024episignaturesinpractice pages 1-2): Thomas Husson, François Lecoquierre, Gaël Nicolas, Anne-Claire Richard, Alexandra Afenjar, Séverine AUDEBERT-BELLANGER, Catherine Badens, Frédéric Bilan, Varoona Bizaoui, Anne Boland, Marie-Noelle Bonnet-Dupeyron, Elise Brischoux-Boucher, Céline Bonnet, Marie Bournez, Odile Boute, Perrine Brunelle, Roseline Caumes, Perrine Charles, Nicolas Chassaing, Nicolas Chatron, Benjamin Cogné, Estelle Colin, Valérie Cormier-Daire, Rodolphe Dard, Benjamin Dauriat, Julian Delanne, Jean-François Deleuze, Florence Demurger, Anne-Sophie Denommé-Pichon, Christel Depienne, Anne Dieux Coeslier, Christèle Dubourg, Patrick Edery, salima EL CHEHADEH, Laurence Faivre, Mélanie FRADIN, Aurore Garde, David Geneviève, Brigitte Gilbert-Dussardier, Cyril Goizet, Alice Goldenberg, Evan Gouy, Anne-Marie Guerrot, Anne Guimier, Ines HARZALLAH, Delphine Héron, Bertrand Isidor, Xavier Le Guillou Horn, Boris Keren, Alma Kuechler, Elodie Lacaze, Alinoë Lavillaureix, Daphné Lehalle, Gaetan Lesca, James Lespinasse, Jonathan Levy, Stanislas Lyonnet, Godelieve Morel, Nolwenn Jean Marçais, Sandrine Marlin, Luisa Marsili, Cyril Mignot, Sophie Nambot, Mathilde Nizon, Robert Olaso, Laurent PASQUIER, Laurine Perrin, Florence Petit, Amélie Piton, Fabienne Prieur, Audrey Putoux, Marc Planes, Sylvie Odent, Chloé Quelin, Sylvia Quemener, Mélanie Rama, Marlène RIO, Massimiliano Rossi, Elise Schaefer, Sophie Rondeau, Pascale SAUGIER-VEBER, Thomas Smol, Sabine Sigaudy, Renaud TOURAINE, Frédéric Tran-Mau-Them, Aurélien Trimouille, Clémence Vanlerberghe, Valérie Vantalon, Gabriella Vera, Marie Vincent, Alban Ziegler, Olivier Guillin, Dominique Campion, and Camille Charbonnier. Episignatures in practice: independent evaluation of published episignatures for the molecular diagnostics of ten neurodevelopmental disorders. European Journal of Human Genetics, 32:190-199, Oct 2024. URL: https://doi.org/10.1038/s41431-023-01474-x, doi:10.1038/s41431-023-01474-x. This article has 38 citations and is from a domain leading peer-reviewed journal.

12. (trajkova2024dnamethylationanalysis pages 1-2): Slavica Trajkova, Jennifer Kerkhof, Matteo Rossi Sebastiano, Lisa Pavinato, Enza Ferrero, Chiara Giovenino, Diana Carli, Eleonora Di Gregorio, Roberta Marinoni, Giorgia Mandrile, Flavia Palermo, Silvia Carestiato, Simona Cardaropoli, Verdiana Pullano, Antonina Rinninella, Elisa Giorgio, Tommaso Pippucci, Paola Dimartino, Jessica Rzasa, Kathleen Rooney, Haley McConkey, Aleksandar Petlichkovski, Barbara Pasini, Elena Sukarova-Angelovska, Christopher M. Campbell, Kay Metcalfe, Sarah Jenkinson, Siddharth Banka, Alessandro Mussa, Giovanni Battista Ferrero, Bekim Sadikovic, and Alfredo Brusco. Dna methylation analysis in patients with neurodevelopmental disorders improves variant interpretation and reveals complexity. Human Genetics and Genomics Advances, 5:100309, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100309, doi:10.1016/j.xhgg.2024.100309. This article has 18 citations and is from a peer-reviewed journal.

13. (tillotson2023anewmouse pages 16-22): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

14. (tillotson2023anewmouse pages 13-16): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

15. (tillotson2023anewmouse pages 10-13): Rebekah Tillotson, Keqin Yan, Julie Ruston, Taylor de Young, Alex Córdova, Valérie Turcotte- Cardin, Yohan Yee, Christine Taylor, Shagana Visuvanathan, Christian Babbs, Evgueni A Ivakine, John G Sled, Brian J Nieman, David J Picketts, and Monica J Justice. A new mouse model of atr-x syndrome carrying a common patient mutation exhibits neurological and morphological defects. Human Molecular Genetics, 32:2485-2501, Jan 2023. URL: https://doi.org/10.1101/2023.01.25.525394, doi:10.1101/2023.01.25.525394. This article has 9 citations and is from a domain leading peer-reviewed journal.

16. (geysens2024nanoporesequencingbasedepisignature pages 11-14): Mathilde Geysens, Benjamin Huremagic, Erika Souche, Jeroen Breckpot, Koenraad Devriendt, Hilde Peeters, Griet Van Buggenhout, Hilde Van Esch, Kris Van Den Bogaert, and Joris Robert Vermeesch. Nanopore sequencing-based episignature detection. MedRxiv, Apr 2024. URL: https://doi.org/10.1101/2024.04.19.24305959, doi:10.1101/2024.04.19.24305959. This article has 3 citations.

17. (mizuguchi2025diagnosticutilityof pages 1-2): Takeshi Mizuguchi, Nobuhiko Okamoto, Taiki Hara, Naoto Nishimura, Masamune Sakamoto, Li Fu, Yuri Uchiyama, Naomi Tsuchida, Kohei Hamanaka, Eriko Koshimizu, Atsushi Fujita, Kazuharu Misawa, Kazuhiko Nakabayashi, Satoko Miyatake, and Naomichi Matsumoto. Diagnostic utility of single-locus dna methylation mark in sotos syndrome developed by nanopore sequencing-based episignature. Clinical Epigenetics, Feb 2025. URL: https://doi.org/10.1186/s13148-025-01832-0, doi:10.1186/s13148-025-01832-0. This article has 1 citations and is from a peer-reviewed journal.

18. (bertocchi2025matrixmetalloproteinase9and pages 57-61): I Bertocchi, F Tempia, E Hoxha, and A Oberto. Matrix metalloproteinase-9 and perineuronal nets as new therapeutic targets for fragile x syndrome (fxs). Unknown journal, 2025.

19. (lupu2024pyridostigmineasa pages 1-2): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

20. (lupu2024pyridostigmineasa pages 3-4): V. V. Lupu, S. Gürsoy, F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, and S. Savasta. Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr-x syndrome. case report and literature review. Frontiers in Pediatrics, Dec 2024. URL: https://doi.org/10.3389/fped.2024.1460658, doi:10.3389/fped.2024.1460658. This article has 2 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03